Reference-Standard Material Qualification - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Reference-Standard Material Qualification
The author reviews the types of reference-standard materials used in drug-product manufacturing, discusses current regulatory requirements, and outlines a reference-standard qualification program.


Pharmaceutical Technology
Volume 33, Issue 4, pp. 66-73

For the initial lot, an example requalification period may be 3, 6, and 12 months for the first year and annually thereafter. In this scenario, it is recommended that during development, the reference standard be assessed after 3 months at the intended storage condition and at an accelerated storage condition. Validation of the analytical method for organic impurities should occur after the full accelerated storage condition has been evaluated. The total length of the requalification program will depend on the intended life of the reference standard and the length of the stability and clinical programs. If the initial lot is proven to be stable for at least one year, then subsequent lots will require annual requalification only. In all study scenarios, a protocol is required to outline the reference-standard material, lot, storage conditions, frequency of test, analytical procedures, acceptance criteria, and reporting criteria.

Distribution and control. Reference-standard materials are often expensive to manufacture and are generally of limited supply. It is important, therefore, to consider how the material will be stored, distributed, and controlled. Once the storage conditions are ascertained, the reference-standard material should be monitored continually using a suitable environmental monitoring system. It is advisable to store the material in at least two different locations in case there is a prolonged excursion from the storage condition. The material should be stored in a secure environment with controlled access and distribution.

David Browne is manager of stability and pharmaceutical testing at Intertek Pharmaceutical Services, d/b/a QTI, 291 Route 22 East, Whitehouse, NJ 08888, tel. 908.534.4445,
.

Submitted: Mar. 20, 2008. Accepted: Sept. 22, 2008.




What would you do differently? Submit your comments about this paper in the space below.

References

1. FDA, "Reviewer Guidance, Validation of Chromatographic Methods" (Rockville, MD), 1994.

2. USP 30–NF 25 General Chapter <11>, "Reference Standards," p. 1.

3. FDA, "Guideline for Submitting Samples and Analytical Data for Methods Validation" (Rockville, MD), 1987.

4. ICH, Q3A(R2) Impurities in New Drug Substances (Geneva, Switzerland), Oct. 25, 2006.

5. USP 30 –NF 25 General Chapter <467>, "Residual Solvents."

6. ICH, Q2(R1) Validation of Analytical Procedures: Text and Methodology (Geneva, Switzerland), Oct. 1994.

7. ICH, Q1A(R2) Stability Testing of New Drug Substances and Products (Geneva, Switzerland), Feb. 6, 2003.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here